Activated prothrombin complex concentrates: approaches to their preparation.
Locally produced prothrombin complex concentrate was activated by different methods and the resultant inhibitor bypassing activity compared with commercially produced activated concentrates using an assay based on the shortening of the clotting time of haemophilic plasma containing inhibitor to factor VIII. Analytical chromatography suggested that for most of these products the inhibitor bypassing activity could be explained in terms of classical activated coagulation factors. In addition, a preparation of Bridge Anticoagulant Neutralising Activity was examined. The results indicate this product merits in vivo investigation as a possible treatment for inhibitor patients.
D001779:Blood Coagulation Factors / Q000378:metabolism*; D002847:Chromatography, Agarose; D005164:Factor IX / Q000378:metabolism; D015949:Factor IXa; D006801:Humans; D010314:Partial Thromboplastin Time; D010714:Phosphatidylethanolamines / Q000494:pharmacology; D011517:Prothrombin Time; D012822:Silicon Dioxide / Q000494:pharmacology; D013925:Thromboplastin / Q000494:pharmacology
D001779:Blood Coagulation Factors; D010714:Phosphatidylethanolamines; C025667:prothrombin complex concentrates; D012822:Silicon Dioxide; D005164:Factor IX; D013925:Thromboplastin; D015949:Factor IXa